rTMS for Executive Function Deficits in Autism Spectrum Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2018-05-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the investigators will be examining the effects of repetitive transcranial magnetic stimulation (rTMS) on executive function deficits in individuals with autism spectrum disorder. Half of the participants will be chosen by chance to receive active rTMS stimulation while half will be chosen by chance to receive sham rTMS. Sham rTMS will feel the same as active rTMS only there will be no direct brain stimulation. This is necessary to ensure that active rTMS is efficacious in the enhancement of executive function in individuals with autism spectrum disorder. Based on results from a recently published pilot study, the investigators propose that active rTMS treatment will result in a significant improvement in working memory performance compared to sham rTMS treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of rTMS on the Abnormal Executive Function of ASD Children

NCT04237870

Executive Dysfunction ASD

UNKNOWN NA

Cortical Excitability and Role of Non Invasive Brain Stimulation in ADHD and AUTISM

NCT07315217

Cortical Excitability Brain Stimulation ADHD +1 more

NOT_YET_RECRUITING NA

Therapeutic Use of rTMS in Pediatric ASD and ADHD Cohorts

NCT06069323

Autism Spectrum Disorder ADHD Neurodevelopmental Disorders

RECRUITING NA

rTMS to Improve Motor Function in Autism

NCT06497920

Autism Spectrum Disorder Motor Activity

RECRUITING NA

rTMS for Depression in Young Adults With Autism

NCT04972136

Autism Spectrum Disorder Major Depressive Disorder

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized, double blind, sham controlled study to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) as a treatment for executive function deficits in individuals with autism spectrum disorder between 16 and 25 years of age. The study duration is approximately 3 months, with the rTMS sessions lasting for 4 weeks, 5 times a week, for about 1 hour each. Several scales will be used to assess for symptom severity and adaptive functioning. Cognition will be assessed using a validated battery.

This study also involves a type of brain imaging known as magnetic resonance imaging (MRI) at the beginning and at the end of the 4 weeks of daily rTMS to better understand the effects of rTMS on brain structure and function. Investigators will measure the size and connections of different parts of the brain to assess brain structure and blood flow while participants are completing some basic tasks to asses brain function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active rTMS

Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 simulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left than right) will be held constant for all 20 treatments.

Intervention: Device: Repetitive Transcranial Magnetic Stimulation

Group Type ACTIVE_COMPARATOR

Repetitive Transcranial Magnetic Stimulation

Intervention Type DEVICE

rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.

Sham rTMS

Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.

Intervention: Device: Repetitive Transcranial Magnetic Stimulation

Group Type SHAM_COMPARATOR

Repetitive Transcranial Magnetic Stimulation

Intervention Type DEVICE

rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Repetitive Transcranial Magnetic Stimulation

rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MagPro x100 series (Medtronic A/S, Copenhagen, Denmark)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are fluent in the English language
* Have a diagnosis of high functioning ASD (HF-ASD) (i.e., are verbal with an Intelligence Quotient (IQ) ≥ 70)
* Are competent to consent based on the subjects' ability to provide a spontaneous narrative description of the key elements of the study
* Are clinically stable as determined by their treating physician, with no medication changes over the past 4 weeks

* Are fluent in the English language
* Competent to consent

Exclusion Criteria

* Have a history of substance abuse or dependence in the last 6 months or have a positive urine toxicology screen
* Have a concomitant major medical or neurologic illness
* Have had a seizure in the past, or have a first-degree relative with epilepsy
* Have an abnormal clinical EEG
* Are pregnant or likely to get pregnant during the next 4 weeks
* Are clinically unstable
* Are on benzodiazepines or anticonvulsant medication
* Have a history of rTMS treatment.

* Have a history of substance abuse or dependence in the last 6 months or have a positive urine toxicology screen
* Have a major medical or neurologic illness
* Have a diagnosed learning disorder or impaired academic or adaptive functioning on history
* Are pregnant
* Have an IQ \< 80
* Have a psychiatric diagnosis on diagnostic interview assessments.

Minimum Eligible Age

16 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes